Butchertown Clinical Trials and The Eye Care Institute Announce Our 19th FDA Approval, XDEMVY™, a novel eyedrop for the treatment of Demodex blepharitis

For Immediate Release – July 25, 2023

Tarsus Pharmaceuticals, Inc., Irvine, CA, announced the U.S. Food and Drug Administration (FDA) has approved XDEMVY (lotilaner ophthalmic solution) 0.25%, indicated for the treatment of Demodex blepharitis.

XDEMVY is the first and only FDA-approved treatment for Demodex blepharitis (DB).

Tarsus states Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. — or 1 out of every 12 adults. It is a common yet often misdiagnosed or underdiagnosed eyelid disease that is caused by an infestation of Demodex mites, the most common ectoparasite found on human skin.

While useful for millions of active Americans, this new treatment may be especially beneficial for nursing home residents and others with less active lifestyles who previously had no treatment options for the condition.

John C. Meyer, MD, of The Eye Care Institute and Butchertown Clinical Trials, was the Principal Investigator. Dr. Meyer was encouraged by the results as soon as he began seeing the effects of the trial drug. Working with the Butchertown Clinical Trials staff, Dr. Meyer enrolled more than 120 Louisville-area patients in this trial.

This is the 19th FDA-approved drug or device for Louisville, KY-based Butchertown Clinical Trials, a division of The Eye Care Institute. Each FDA approval represents a breakthrough for medicine and for the improvement of the lives of our patients.

# # #

For more information, contact Butchertown Clinical Trials.